Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study

[1]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[2]  H. Gwak,et al.  Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity , 2019, Breast Cancer Research and Treatment.

[3]  H. Gwak,et al.  Factors Influencing Imatinib-Induced Hepatotoxicity , 2019, Cancer research and treatment : official journal of Korean Cancer Association.

[4]  H. Gwak,et al.  Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients , 2018, Medical Oncology.

[5]  H. Gwak,et al.  Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study , 2018, BMC Cancer.

[6]  H. Gwak,et al.  Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity , 2018, Anti-cancer drugs.

[7]  H. Gwak,et al.  Effects of Concomitant Medication Use on Gefitinib‐Induced Hepatotoxicity , 2018, Journal of clinical pharmacology.

[8]  E. Basch,et al.  The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events , 2018, Journal of Patient-Reported Outcomes.

[9]  S. Krähenbühl,et al.  Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis , 2017, Front. Pharmacol..

[10]  X. Wang,et al.  Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters , 2016, The Pharmacogenomics Journal.

[11]  J. Sloan,et al.  The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. , 2015, Journal of the National Cancer Institute.

[12]  N. Iqbal,et al.  Imatinib: A Breakthrough of Targeted Therapy in Cancer , 2014, Chemotherapy research and practice.

[13]  E. Estey,et al.  The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. , 2013, Blood.

[14]  R. Shah,et al.  Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives , 2013, Drug Safety.

[15]  R. Shah,et al.  Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval) , 2013, Drug Safety.

[16]  Joel Morganroth,et al.  Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy , 2013, Drug Safety.

[17]  J. Ware,et al.  Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH‐Dependent Solubility the Achilles Heel of Targeted Therapy? , 2012, Clinical pharmacology and therapeutics.

[18]  Hyae-Young Kim,et al.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Yap,et al.  Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence , 2012, Breast Cancer Research and Treatment.

[20]  T. Choueiri,et al.  Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. , 2011, Critical reviews in oncology/hematology.

[21]  R. Altman,et al.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). , 2011, Pharmacogenetics and genomics.

[22]  M. Cameron,et al.  Metabolism considerations for kinase inhibitors in cancer treatment , 2010, Expert opinion on drug metabolism & toxicology.

[23]  A. Gemma,et al.  F1000 highlights , 2010 .

[24]  J. Senior.  Unintended Hepatic Adverse Events Associated with Cancer Chemotherapy , 2010, Toxicologic pathology.

[25]  Deborah A. Smith,et al.  Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. , 2009, British journal of clinical pharmacology.

[26]  M. Chen,et al.  Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics , 2008, Circulation.

[27]  M. Meyerson,et al.  Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[28]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[29]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  M. Perry,et al.  Hepatotoxicity of chemotherapy. , 2001, Expert opinion on drug safety.

[31]  D A Smith,et al.  Role of reactive metabolites in drug-induced hepatotoxicity. , 2010, Handbook of experimental pharmacology.